Company Profile

STATegics, Inc. is structured around discovery and development of breakthrough new treatments for life-threatening rare neurodegenerative diseases. The firm is developing small molecule agonists of the tissue-protective receptor for treatment of CNS and rare diseases, including Friedreich’s ataxia and Parkinson’s disease, with potential for additional opportunities in Alzheimer’s disease, ALS, multiple sclerosis, schizophrenia, depresion and peripheral neuropathy. By targeting the tissue-protective cytokine receptor, STATegics has identified novel small molecules to address the underlying cause of Friedreich’s ataxia (FA), a rare neuromuscular disease for which no treatment is available. In addition to addressing critical drivers in FA, STATegics’ molecules have the potential to treat multiple neuromuscular and neurodegenerative